Jason Butler
Stock Analyst at Citizens Capital Markets
(3.51)
# 931
Out of 4,761 analysts
136
Total ratings
42.42%
Success rate
7.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRTA Prothena Corporation | Reiterates: Market Outperform | $80 | $15.56 | +414.14% | 8 | Feb 21, 2025 | |
| DVAX Dynavax Technologies | Maintains: Market Outperform | $29 → $33 | $13.33 | +147.56% | 1 | Feb 21, 2025 | |
| RZLT Rezolute | Maintains: Market Outperform | $8 → $9 | $4.53 | +98.68% | 8 | Feb 13, 2025 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $50.26 | +55.19% | 14 | Feb 7, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $5 | $1.91 | +161.78% | 8 | Jan 14, 2025 | |
| ARGX argenx SE | Maintains: Market Outperform | $606 → $696 | $644.48 | +7.99% | 7 | Jan 14, 2025 | |
| ABVX ABIVAX Société Anonyme | Initiates: Market Outperform | $33 | $8.08 | +308.42% | 1 | Dec 4, 2024 | |
| VIGL Vigil Neuroscience | Reiterates: Market Outperform | $22 | $3.03 | +626.07% | 4 | Nov 26, 2024 | |
| SYRS Syros Pharmaceuticals | Downgrades: Market Perform | n/a | $0.17 | - | 4 | Nov 13, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $72 → $73 | $57.75 | +26.41% | 13 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $3.01 | +199.00% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $17 | $7.68 | +121.35% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $39 | $12.51 | +211.75% | 4 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.43 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $50 → $23 | $1.78 | +1,192.13% | 3 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $10.13 | +87.56% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $39 | $19.95 | +95.49% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $16.27 | +133.56% | 7 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $1.82 | +1,112.12% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.82 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $1,200 | $0.32 | +375,722.11% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $8.03 | +1,344.58% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $3.42 | +163.16% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $191 → $111 | $1.82 | +5,998.90% | 6 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.62 | - | 1 | Dec 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $24 → $21 | $128.60 | -83.67% | 5 | Aug 8, 2019 |
Prothena Corporation
Feb 21, 2025
Reiterates: Market Outperform
Price Target: $80
Current: $15.56
Upside: +414.14%
Dynavax Technologies
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $13.33
Upside: +147.56%
Rezolute
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $4.53
Upside: +98.68%
Cytokinetics
Feb 7, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $50.26
Upside: +55.19%
Precigen
Jan 14, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $1.91
Upside: +161.78%
argenx SE
Jan 14, 2025
Maintains: Market Outperform
Price Target: $606 → $696
Current: $644.48
Upside: +7.99%
ABIVAX Société Anonyme
Dec 4, 2024
Initiates: Market Outperform
Price Target: $33
Current: $8.08
Upside: +308.42%
Vigil Neuroscience
Nov 26, 2024
Reiterates: Market Outperform
Price Target: $22
Current: $3.03
Upside: +626.07%
Syros Pharmaceuticals
Nov 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.17
Upside: -
Halozyme Therapeutics
Nov 1, 2024
Maintains: Market Outperform
Price Target: $72 → $73
Current: $57.75
Upside: +26.41%
Oct 8, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $3.01
Upside: +199.00%
Sep 24, 2024
Initiates: Market Outperform
Price Target: $17
Current: $7.68
Upside: +121.35%
Sep 4, 2024
Reiterates: Market Outperform
Price Target: $39
Current: $12.51
Upside: +211.75%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.43
Upside: -
Jul 26, 2024
Maintains: Market Outperform
Price Target: $50 → $23
Current: $1.78
Upside: +1,192.13%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $10.13
Upside: +87.56%
Mar 12, 2024
Maintains: Outperform
Price Target: $44 → $39
Current: $19.95
Upside: +95.49%
Nov 14, 2023
Maintains: Market Outperform
Price Target: $42 → $38
Current: $16.27
Upside: +133.56%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $1.82
Upside: +1,112.12%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.82
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $1,200
Current: $0.32
Upside: +375,722.11%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $8.03
Upside: +1,344.58%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $3.42
Upside: +163.16%
May 5, 2021
Maintains: Market Outperform
Price Target: $191 → $111
Current: $1.82
Upside: +5,998.90%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $0.62
Upside: -
Aug 8, 2019
Reiterates: Market Outperform
Price Target: $24 → $21
Current: $128.60
Upside: -83.67%